Organogenesis Holdings Inc.
A regenerative-medicine company that grows living skin and tissue grafts to help wounds heal. Its best-known product, Apligraf, was the first living cell-based skin substitute approved by the U.S. Food and Drug Administration, and its PuraPly line treats chronic wounds like diabetic ulcers. Founded in 1985 in Cambridge, Massachusetts, the company's name reflects its mission of growing organs and tissues in the lab.
Bought 5.0K
Bought 10.0K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Leibowitz Arthur SDirector · 1 transaction | +1.7% | 291.0K | — | 5.0K | — |
| Cavorsi RobertVice President, Strategy · 1 transaction | -0.3% | 275.5K | — | — | — |
| Driscoll Michael JosephDirector · 1 transaction | +4.6% | 225.7K | — | 10.0K | — |
Select a row to see that insider’s individual transactions.
Net open-market activity over the last 6 months: +15.0K shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.